51Chromium survival of Yt(a+) red cells as a determinant of the in vivo significance of anti-Yta.
A case is presented in which anti-Yta produced a moderately accelerated removal of chromium-labeled Yt(a+) red blood cells (T1/2, 96 hours). Other reported examples of anti-Yta either have rapidly removed transfused Yt(a+) red blood cells or have permitted apparently normal survival of these cells. In light of this wide variation in in vivo potency of anti-Yta, it is recommended that chromium red blood cell survival studies be done before transfusion of Yt(a+) red blood cells in sensitized individuals.
D000328:Adult; D000743:Anemia, Hemolytic / Q000175:diagnosis; D000937:Antigen-Antibody Reactions; D001665:Binding Sites; D001789:Blood Group Antigens; D001787:Blood Group Incompatibility / Q000175:diagnosis; D002860:Chromium Radioisotopes; D003165:Complement System Proteins / Q000378:metabolism; D004905:Erythrocyte Aging; D005260:Female; D006801:Humans; D007518:Isoantibodies
D001789:Blood Group Antigens; D002860:Chromium Radioisotopes; D007518:Isoantibodies; D003165:Complement System Proteins